← Browse by Condition
Medical Condition

recurrent ovarian carcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for recurrent ovarian carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent ovarian carcinoma Clinical Trials

How many clinical trials are currently recruiting for recurrent ovarian carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for recurrent ovarian carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent ovarian carcinoma?
recurrent ovarian carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent ovarian carcinoma clinical trial?
Eligibility criteria for recurrent ovarian carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
University of Washington 1 trial
Roswell Park Cancer Institute 1 trial
M.D. Anderson Cancer Center 1 trial
National Cancer Institute (NCI) 1 trial

Recruiting Clinical Trials

NCT06295965
Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Enrollment
2,000 pts
Location
United States
Sponsor
University of Washington
View Trial →
NCT06855706
Recruiting
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Enrollment
120 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
View Trial →
NCT03604315 Phase 1
Recruiting
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Enrollment
300 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05564377 Phase 2
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Enrollment
2,900 pts
Location
United States, Puert...
Sponsor
National Cancer Institute (NCI...
View Trial →

Related Conditions

recurrent fallopian tube carcinoma (4) recurrent primary peritoneal carcinoma (4) recurrent malignant solid neoplasm (2) ovarian carcinoma (2) clonal cytopenia of undetermined significance (1) clonal hematopoiesis (1) idiopathic cytopenia of undetermined significance (1) non neoplastic hematopoietic and lymphoid cell disorder (1) myeloid neoplasm post cytotoxic therapy (1) endometrial carcinoma (1) stage ii fallopian tube cancer ajcc v8 (1) stage ii ovarian cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology